89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, Nov. 29, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the "Company" or "89bio") (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 49,800 shares of the Company's common stock to four new employees (the "Inducement Grants") on November 25, 2024 (the "Grant Date"). The Inducement Grants have been granted pursuant to the Company's 2023 Inducement Plan (the "Plan"). The Inducement Grants were granted as an inducement material to these individuals entering into employment with 89bio in accordance with Nasdaq Listing Rule 5635(c)(4).
2024年11月29日，美國加州舊金山（全球新聞專線）- 89bio公司（以下簡稱"公司"或"89bio"）（納斯達克股票代碼：ETNB）是一家臨床階段生物製藥公司，專注於開發和商業化治療肝臟和心臟代謝疾病的創新療法。今日，公司董事會薪酬委員會批准了向四名新員工發放非合格股票期權，購買公司普通股總數爲49,800股（以下簡稱"誘因授予"），日期爲2024年11月25日（以下簡稱"授予日期"）。誘因授予根據公司的2023年誘因計劃（以下簡稱"計劃"）授予。根據納斯達克上市規則5635(c)(4)，誘因授予是爲了吸引這些個人按照規定的日期與89bio公司簽訂僱傭協議而授予的。
The Inducement Grants have an exercise price per share that is equal to the closing price of 89bio's common stock on the Grant Date. The Inducement Grants will vest over a four-year period, with 25% of the shares vesting on the one-year anniversary of the employee's start date, and thereafter the remainder of the shares vest in 12 equal quarterly installments, subject to each employee's continued employment with 89bio through the applicable vesting dates.
誘因授予的行權價格等於89bio公司在授予日期的收盤價。誘因授予將在四年內解鎖，員工入職一週年之日解鎖25%的股份，其後剩餘股份將分爲12個等額季度解鎖，取決於員工在適用解鎖日期時繼續受僱於89bio。
About 89bio
89bio is a clinical-stage biopharmaceutical company dedicated to the development of best-in-class therapies for patients with liver and cardiometabolic diseases who lack optimal treatment options. The company is in Phase 3 studies for its lead candidate pegozafermin for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and severe hypertriglyceridemia (SHTG). Pegozafermin is a specifically engineered, potentially best-in-class fibroblast growth factor 21 (FGF21) analog with unique glycoPEGylated technology that optimizes biological activity through an extended half-life. The company is headquartered in San Francisco. For more information, visit or follow the company on LinkedIn.
關於89bio 89bio是一家專注於爲患有肝臟和代謝性疾病的患者開發最佳療法的臨床階段生物製藥公司。該公司致力於通過臨床發展其領先候選藥物pegozafermin，用於治療代謝性功能障礙相關脂肪肝（MASH）和嚴重高三酰甘油血癥（SHTG）。Pegozafermin是一種經過特殊設計的、潛在的最佳成長因子21類似物（FGF21類似物），通過糖基PEG化技術優化生物活性，並具有延長半衰期的特點。公司總部位於舊金山。欲了解更多信息，請訪問www.89bio.com或關注該公司的
89bio是一家專注於開發肝臟和心臟代謝疾病患者的最佳療法的臨床階段生物製藥公司，這些患者缺乏最佳的治療選擇。該公司正在進行其主力候選藥peg卡費明治療代謝功能紊亂相關性脂肪肝（MASH）和嚴重高三酰甘油血癥（SHTG）的3期研究。Pegozafermin是一種經過特殊設計的、具有獨特的糖基PEG化技術的可能是最佳的成纖維細胞生長因子21（FGF21）類似物，通過延長半衰期來優化生物活性。該公司總部設在舊金山。欲了解更多信息，請訪問或關注該公司的LinkedIn。
Investor Contact:
Annie Chang
89bio, Inc.
investors@89bio.com
投資者聯繫人：
Annie Chang
89bio公司
investors@89bio.com
PJ Kelleher
LifeSci Advisors, LLC
+1-617-430-7579
pkelleher@lifesciadvisors.com
PJ Kelleher
LifeSci Advisors, LLC
+1-617-430-7579
pkelleher@lifesciadvisors.com
Media Contact:
Sheryl Seapy
Real Chemistry
sseapy@realchemistry.com
媒體聯繫：
Sheryl Seapy
Real Chemistry
sseapy@realchemistry.com
譯文內容由第三人軟體翻譯。
